Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
- General Information About Adult Non-Hodgkin Lymphoma (NHL)
- Late Effects of Treatment for Adult NHL
- Cellular Classification of Adult NHL
- Indolent NHL
- Aggressive NHL
- Stage Information for Adult NHL
- Treatment Option Overview for Adult NHL
- Treatment for Indolent, Stage I and Contiguous Stage II Adult NHL
- Treatment for Indolent, Noncontiguous Stage II/III/IV Adult NHL
- Treatment for Indolent, Recurrent Adult NHL
- Treatment for Aggressive, Stage I and Contiguous Stage II Adult NHL
- Treatment for Aggressive, Noncontiguous Stage II/III/IV Adult NHL
- Treatment for Adult Lymphoblastic Lymphoma (ALL)
- Treatment for Diffuse, Small Noncleaved-Cell/Burkitt Lymphoma
- Treatment for Aggressive, Recurrent Adult NHL
- NHL During Pregnancy
- Changes to This Summary (04/20/2018)
- About This PDQ Summary
- View All Sections
Changes to This Summary (04/20/2018)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Prince et al. as reference 57 and Pro et al. as reference 58. Added text to state that in a phase II study, 66% of 58 patients attained a complete response with brentuximab vedotiin, and at a median follow-up of 58 months, the 5-year progression-free survival (PFS) was 57%, and the 5-year overall survival (OS) was 79% with 42% of these patients undergoing autologous stem cell transplantation (ASCT) (added level of evidence 3iiiDiv).
Revised text to state that the increased risk of central nervous system involvement and of local recurrence has led to recommendations for radiation therapy locally, concurrently, before the start of chemotherapy or between cycle two and three of chemotherapy, and for intrathecal prophylaxis and/or prophylactic cranial radiation therapy (cited Vargo et al. as reference 73). Revised text to state that low-risk patients fared best with radiation therapy alone, while high-risk patients fared best with a strategy of radiation therapy concurrent with chemotherapy, following cycle two of chemotherapy or followed by chemotherapy. Also added that higher doses of radiation therapy administered at more than 50 Gy are associated with improved outcomes according to anecdotal reports.
Added Carson et al. as reference 102.
Added Cohen et al. as reference 173.
Added text to state that a randomized trial that compared bendamustine plus rituximab (BR) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone failed to show any benefit for rituximab maintenance after BR.
Added text to state that in a prospective trial of 299 patients who were previously untreated for mantle cell lymphoma, 257 responders received four courses of rituximab, dexamethasone, cytarabine, and cisplatin and ASCT. The patients were randomly assigned to rituximab maintenance therapy for 3 years versus no maintenance therapy. After randomization, a median follow-up at 50.2 months showed the rate of PFS at 4-years favored the rituximab-maintenance group at 83% versus the no-maintenance group at 64%. The 4-year OS rate also favored the rituximab-maintenance group at 89% versus the no-maintenance group at 80% (cited Le Gouill as reference 188 and level of evidence 1iiA).
Added obinutuzumab as a standard treatment option for indolent, noncontiguous stage II/III/IV adult NHL
Added Obinutuzumab as a new subsection.
Added Chiappella et al. as reference 48.
Added Other treatment options as a new subsection.
Added text to state that in one anecdotal case, a newborn exposed to a rituximab-containing regimen in utero was born with no circulating B lymphocytes. Added that the newborn was otherwise normal and recovered the circulating B lymphocytes by age 6 months with no unusual or persisting intercurrent infections (cited Mandal et al. as reference 11).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
< Previous section
NHL During Pregnancy
NHL During Pregnancy
Next section >
About This PDQ Summary
About This PDQ Summary
No hay comentarios:
Publicar un comentario